In contrast, several studies with SSAs (octreotide LAR, lanreotide) in gastric NETs type 1 (associated with chronic atrophic gastritis) and type 2 (associated with Zollinger-Ellison syndrome) have been shown to inhibit gastrin secretion (decreases or normalizes gastric secretion in 50–100% of gastrinomas) and to reduce tumor burden, achieving tumor stabilization in 47–75% of patients. The gene discussed is GAST; the disease is neoplasm.